

**RECEIVED**

MAY 24 2002

TECH CENTER 1600/2900

Sheet 1 of 1

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office	Docket No. <b>CARP-0089</b>	Serial No. <b>09/875,221</b>
	Applicant <b>Athwal et al.</b>	
	Filing Date <b>June 6, 2001</b>	Group <b>1646</b>

**U. S. PATENT DOCUMENTS**

Examiner Initial		Document No.	Date	Name	Class	Subclass

**FOREIGN PATENT DOCUMENTS**

Examiner Initial		Document No.	Date	Country	Translation	
					YES	NO
EMA	BX	89/00195 A1	01/12/89	WO		
↓	BY	89/01476 A1	02/23/89	WO		
✓	BZ	93/06231 A1	04/01/93	WO		

EXAMINER

Eileen B O'Hara

DATE CONSIDERED

4/18/03

File Copy

RECEIVED

APR 24 2002

TECH CENTER 1600/2900

## Form PTO-1449 Modified

Docket No.  
CARP-0089Serial No.  
09/875,221

List of Patent and Publications  
Cited by Applicant  
(Use several sheets if necessary)

Applicant  
Athwal et al.

U.S. Department of Commerce  
Patent and Trademark Office

Filing Date  
June 6, 2001Group  
1646

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EMA	AA	Adorini <i>et al.</i> , "Pathogenesis and immunotherapy of autoimmune diseases," Trends in Immunology Today, <u>18</u> , 209-211, 1997
EMA	AB	Arnett <i>et al.</i> , "The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis," Arthritis Rheum., <u>31</u> (1), 315-324, 1988
	AC	Beutler <i>et al.</i> , "Shock and tissue injury induced by recombinant human cachetin," Science, <u>234</u> , 470-474, 1985
	AD	Bodmer <i>et al.</i> , "Preclinical review of anti-tumor necrosis factor monoclonal antibodies," Critical Care Medicine, <u>21</u> (10), S441-S446, 1993
	AE	Boers <i>et al.</i> , "World Health Organization and International League of Associations for Rheumatology Care Endpoints for Symptom Modifying Antirheumatic Drugs in Rheumatoid Arthritis Clinical Trials," J. Rheumatol - Supplement 41, <u>21</u> , 86-89, 1994
	AF	Chapman, A.P. <i>et al.</i> , "Therapeutic antibody fragments with prolonged in vivo half lives," Nature Biotechnology <u>17</u> , 780-783, 1999
	AG	Crameri <i>et al.</i> , "DNA shuffling of a family of genes from diverse species accelerates directed evolution," Nature, <u>391</u> , 288-291, 1998
	AH	Elliott <i>et al.</i> , "Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor $\alpha$ (cA2) versus placebo in rheumatoid arthritis," Lancet, <u>344</u> , 1105-1110, 1994
	AI	Feldmann <i>et al.</i> , Anti-Tumor Necrosis Factor- $\alpha$ Therapy of Rheumatoid Arthritis," Advances in Immunology, <u>64</u> , 283-350, 1997
✓	AJ	Feldman <i>et al.</i> , "Anti-TNF $\alpha$ Therapy is Useful in Rheumatoid Arthritis and Crohn's Disease: Analysis of the Mechanism of Action Predicts Utility in Other Diseases," Transplantation Proceedings, <u>30</u> , 4126-4127, 1998

EXAMINER

Eden B. O'Hara

DATE CONSIDERED

4/18/03

RECEIVED

APR 25 2002

OFFICE OF PETITIONS

File Copy



RECEIVED

APR 25 2002

OFFICE OF PETITIONS  
Sheet 2 of 5

## Form PTO-1449 Modified

Docket No.  
CARP-0089Serial No.  
09/875,221Applicant  
Athwal et al.Filing Date  
June 6, 2001Group  
1646List of Patent and Publications  
Cited by Applicant  
(Use several sheets if necessary)U.S. Department of Commerce  
Patent and Trademark Office

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EA	AK	Felson <i>et al.</i> , American College of Rheumatology Preliminary Definition of Improvement in Rheumatoid Arthritis," <i>Arthritis Rheum.</i> , <u>38</u> , 727-735, 1995
	AL	Fendly <i>et al.</i> , "Murine Monoclonal Antibodies Defining Neutralizing Epitopes on Tumor Necrosis Factor," <i>Hybridoma</i> , <u>6(4)</u> , 359-370, 1987
	AM	Flanagan <i>et al.</i> , "Arrangement of human immunoglobulin heavy chain constant region genes implies evolutionary duplication of a segment containing $\gamma$ , $\epsilon$ and $\alpha$ genes," <i>Nature</i> , <u>300</u> , 709-713, 1982
	AN	Hieter <i>et al.</i> , Genbank Accession No. J00241 "Human Ig germline kappa-L chain, C region (inv3 allele)." January 5, 1995
	AO	Hieter <i>et al.</i> , "Cloned Human and Mouse Kappa Immunoglobulin Constant and J Region Genes Conserve Homology in Functional Segments," <i>Cell</i> , <u>22</u> , 197-207, 1980
	AP	Keffer <i>et al.</i> , "Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis," <i>EMBO J.</i> , <u>10(13)</u> , 4025-4031, 1991
	AQ	Kirschenbaum <i>et al.</i> , "Antibodies to TNF- $\alpha$ : Too little, too late?" <i>Critical Care Medicine</i> , <u>26(10)</u> , 1625-1626, 1998
	AR	Low <i>et al.</i> , "Mimicking somatic hypermutation: Affinity Maturation of Antibodies Displayed on Bacteriophage Using a Bacterial Mutator Strain," <i>J. Mol. Biol.</i> , <u>260</u> , 359-368, 1996
	AS	Maini <i>et al.</i> , "Clinical response of Rheumatoid Arthritis (RA) to anti-TNF $\alpha$ (cA2) monoclonal antibody (mab) is related to administered dose and persistence of circulating antibody," <i>Arthritis Rheum.</i> , <u>38(9)</u> , (Supplement) : S186, 1995
✓	AT	Maini <i>et al.</i> , "Infliximab (chimeric anti-tumour necrosis factor $\alpha$ monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial," <i>Lancet</i> , <u>354</u> , 1932-1939, 1999

EXAMINER

Eileen B. O'Hara

DATE CONSIDERED

4/18/03



TECH CENTER 1600/2900

APR 24 2002

RECEIVED

RECEIVED

APR 25 2002

OFFICE OF PETITIONS

Sheet 3 of 5

## Form PTO-1449 Modified

Docket No.  
CARP-0089Serial No.  
09/875,221Applicant  
Athwal et al.Filing Date  
June 6, 2001Group  
1646List of Patent and Publications  
Cited by Applicant  
(Use several sheets if necessary)U.S. Department of Commerce  
Patent and Trademark Office

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EA	AU	Marks <i>et al.</i> , "By-passing immunization: Building high affinity human antibodies by chain shuffling," Bio/Technology, <u>10</u> , 779-783, 1992
	AV	McKown <i>et al.</i> , "Lack of efficacy of oral bovine type II collagen added to existing therapy in rheumatoid arthritis," Arthritis Rheum., <u>42</u> (6), 1204-1208, 1999
	AW	Meager <i>et al.</i> , "Preparation and characterization of monoclonal antibodies directed against antigenic determinants of recombinant human tumour necrosis factor (rTNF)," Hybridoma, <u>6</u> (3), 305-311, 1987
	AX	Moreland <i>et al.</i> , "Etanercept therapy in Rheumatoid Arthritis," Ann Intern Med., <u>130</u> , 478-486, 1999
	AY	Patten <i>et al.</i> , "Applications of DNA shuffling to pharmaceuticals and vaccines," Curr. Opin. Biotechnol., <u>8</u> , 724-733, 1997
	AZ	Prevoo <i>et al.</i> , "Modified disease activity scores that include twenty-eight-joint counts," Arthritis Rheum., <u>38</u> , 44-48, 1995
	BA	Rankin <i>et al.</i> , "The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in Rheumatoid Arthritis," British J. Rheumatology, <u>34</u> , 334-342, 1995
	BB	Riechmann <i>et al.</i> , "Reshaping human antibodies for therapy," Nature, <u>332</u> , 323-324, 1988
	BC	Scott <i>et al.</i> , "Disease activity in rheumatoid arthritis: preliminary report of the Consensus Study Group of the European Workshop for Rheumatology Research," Clin. Exp. Rheumatol., <u>10</u> , 521-525, 1992
✓	BD	Shimamoto <i>et al.</i> , "Monoclonal antibodies against human recombinant tumor necrosis factor: prevention of endotoxic shock," Immunology Letters, <u>17</u> , 311-318, 1988

EXAMINER

Eileen B. O'Hara

DATE CONSIDERED

4/18/03



RECEIVED

APR 24 2002

TECH CENTER 1600/2900

RECEIVED

APR 24 2002

TECH CENTER 1600/2900  
Sheet 4 of 5

## Form PTO-1449 Modified

Docket No.  
**CARP-0089**Serial No.  
**09/875,221**List of Patent and Publications  
Cited by Applicant  
(Use several sheets if necessary)Applicant  
**Athwal et al.**U.S. Department of Commerce  
Patent and Trademark OfficeFiling Date  
**June 6, 2001**Group  
**1646**

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EAA	BE	Stephens <i>et al.</i> , "Comprehensive pharmacokinetics of a humanized antibody and analysis of residual anti-idiotypic responses," Immunology, <u>85</u> , 668-674, 1995
	BF	Thompson <i>et al.</i> , "Affinity maturation of a high-affinity human monoclonal antibody against the third hypervariable loop of human immunodeficiency virus: Use of phage display to improve affinity and broaden strain reactivity," J. Mol. Biol., <u>256</u> , 77-88, 1996
	BG	Vaughan <i>et al.</i> , "Human antibodies by design," Nature Biotechnology, <u>16</u> , 535-539, 1998
	BH	Verhoeven <i>et al.</i> Science, "Reshaping Human Antibodies: Grafting an Antilysozyme Activity," <u>239</u> , 1534-1536, 1988
	BI	Wherry <i>et al.</i> , "Tumor necrosis factor and the therapeutic potential of anti-tumor necrosis factor antibodies," Critical Care Medicine, <u>21(10)</u> , S436-S440, 1993
	BJ	Williams <i>et al.</i> "Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis," PNAS-USA, <u>89</u> , 9784-9788, 1992
	BK	Wu <i>et al.</i> , "An analysis of the sequences of the variable regions of Bence Jones proteins and myeloma light chains and their implications for anti-body complementarity," J. Exp. Med., <u>132</u> , 211-250, 1970
✓	BL	Yang <i>et al.</i> , "CDR Walking Mutagenesis for the Affinity Maturation of a Potent Human Anti-HIV-1 Antibody into the Picomolar Range," J. Mol. Biol., <u>254</u> , 392-403, 1995

EXAMINER

Eileen B. O'Hara

DATE CONSIDERED

4/18/03

RECEIVED

APR 25 2002

OFFICE OF PETITIONS

RECEIVED

APR 25 2002

OFFICE OF PETITIONS

Sheet 5 of 5

## Form PTO-1449 Modified

Docket No.  
CARP-0089Serial No.  
09/875,221Applicant  
Athwal et al.Filing Date  
June 6, 2001Group  
1646List of Patent and Publications  
Cited by Applicant  
(Use several sheets if necessary)U.S. Department of Commerce  
Patent and Trademark Office

## U. S. PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Name	Class	Subclass
EVA	BM	5,919,452	07/06/99	Le et al.	424	133.1

## FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Translation YES NO	
EVA	BN	0 392 745 A2	10/17/90	EP		
	BO	0 239 400 A2	09/30/87	EP		
	BP	2 297 145 A	07/24/96	GB		
	BQ	86/01533 A1	03/13/86	WO		
	BR	90/07861 A1	07/26/90	WO		
	BS	91/09967 A1	07/11/91	WO		
	BT	92/11383 A1	07/09/92	WO		
	BU	92/22583 A2	12/23/92	WO		
	BV	98/20734 A1	05/22/98	WO		
✓	BW	98/25971 A1	06/18/98	WO		

EXAMINER

Eileen B. O'Hare

DATE CONSIDERED

4/18/03



RECEIVED